Albireo Pharma, Inc. announced the upcoming departure of Pat Horn, M.D., Ph.D., Chief Medical Officer, who will be leaving at the end of the year 2021 after almost three and a half years with the company. Jan Mattsson, Ph.D., Chief Scientific Officer and co-founder of the company, will be taking over as the interim head of R&D, leading research and development of early and late-stage assets and programs. As one of the co-founders of the company with deep experience in drug development and approvals, Dr. Mattsson is primed to lead the R&D organization with his institutional knowledge, vision for the pipeline and products, and ability to deliver against corporate objectives.